[{"id":"855dd99b-0486-413b-8745-83182704b7d8","acronym":"","url":"https://clinicaltrials.gov/study/NCT02582359","created_at":"2021-01-18T12:31:30.489Z","updated_at":"2025-02-25T14:57:23.823Z","phase":"Phase 1","brief_title":"MLN 9708 in Induction and Consolidation for Adults With AML \u003e= 60 Years of Age","source_id_and_acronym":"NCT02582359","lead_sponsor":"Massachusetts General Hospital","biomarkers":" CD74","pipe":" | ","alterations":" CD74 expression","tags":["CD74"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD74 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • Ninlaro (ixazomib) • daunorubicin"],"overall_status":"Completed","enrollment":" Enrollment 39","initiation":"Initiation: 01/01/2016","start_date":" 01/01/2016","primary_txt":" Primary completion: 04/01/2022","primary_completion_date":" 04/01/2022","study_txt":" Completion: 04/01/2022","study_completion_date":" 04/01/2022","last_update_posted":"2022-08-24"},{"id":"bd5e2f13-5c03-4779-a52a-14cdbde4fbf7","acronym":"","url":"https://clinicaltrials.gov/study/NCT00603668","created_at":"2021-01-18T02:14:23.258Z","updated_at":"2024-07-02T16:36:26.290Z","phase":"Phase 1/2","brief_title":"Phase I/II Study of Different Doses and Dose Schedules of Milatuzumab (hLL1) in CLL","source_id_and_acronym":"NCT00603668","lead_sponsor":"Gilead Sciences","biomarkers":" CD74","pipe":"","alterations":" ","tags":["CD74"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e milatuzumab (IMMU-115)"],"overall_status":"Completed","enrollment":" Enrollment 19","initiation":"Initiation: 08/01/2008","start_date":" 08/01/2008","primary_txt":" Primary completion: 01/01/2013","primary_completion_date":" 01/01/2013","study_txt":" Completion: 02/01/2013","study_completion_date":" 02/01/2013","last_update_posted":"2021-08-16"},{"id":"22f3047f-497a-4d53-92c2-cba42f8848df","acronym":"","url":"https://clinicaltrials.gov/study/NCT02070458","created_at":"2021-01-18T09:32:19.542Z","updated_at":"2024-07-02T16:37:04.698Z","phase":"Phase 1","brief_title":"Ixazomib, Mitoxantrone Hydrochloride, Etoposide, and Intermediate-Dose Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT02070458","lead_sponsor":"Case Comprehensive Cancer Center","biomarkers":" CD74","pipe":"","alterations":" ","tags":["CD74"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • etoposide IV • Ninlaro (ixazomib) • mitoxantrone"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 10/08/2014","start_date":" 10/08/2014","primary_txt":" Primary completion: 03/17/2017","primary_completion_date":" 03/17/2017","study_txt":" Completion: 08/15/2017","study_completion_date":" 08/15/2017","last_update_posted":"2018-12-13"},{"id":"ac25ec3e-fc3f-4378-9027-ddc11a11d079","acronym":"","url":"https://clinicaltrials.gov/study/NCT02761863","created_at":"2021-01-18T13:32:39.989Z","updated_at":"2024-07-02T16:37:13.706Z","phase":"","brief_title":"Effect of Expression of CD74 and VEGF on Outcome of Treatment in Patients With Malignant Pleural Mesothelioma","source_id_and_acronym":"NCT02761863","lead_sponsor":"Ain Shams University","biomarkers":" CD74","pipe":" | ","alterations":" CD74 expression","tags":["CD74"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD74 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pemetrexed"],"overall_status":"Unknown status","enrollment":" Enrollment 100","initiation":"Initiation: 07/30/2019","start_date":" 07/30/2019","primary_txt":" Primary completion: 01/30/2020","primary_completion_date":" 01/30/2020","study_txt":" Completion: 07/30/2021","study_completion_date":" 07/30/2021","last_update_posted":"2018-02-23"},{"id":"e6133b6d-7b6a-46a4-b0fd-ea727d6fbdfd","acronym":"VITMPM","url":"https://clinicaltrials.gov/study/NCT02603315","created_at":"2021-01-18T12:39:00.230Z","updated_at":"2024-07-02T16:37:31.588Z","phase":"","brief_title":"Vascularity Impact on the Treatment Outcome in Malignant Pleural Mesothelioma(VITMPM)","source_id_and_acronym":"NCT02603315 - VITMPM","lead_sponsor":"Ain Shams University","biomarkers":" CD74 • VEGFA","pipe":"","alterations":" ","tags":["CD74 • VEGFA"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 10/01/2015","start_date":" 10/01/2015","primary_txt":" Primary completion: 05/01/2016","primary_completion_date":" 05/01/2016","study_txt":" Completion: 05/01/2016","study_completion_date":" 05/01/2016","last_update_posted":"2016-06-01"}]